Warning letter
Innovative Intrathecal Solutions, Inc. dba Innovative Compounding Pharmacy: warning letter of Sep 19, 2018
FDA warning letter 555295 · San Francisco District Office
Key facts
| Reference number | 555295 |
|---|---|
| Company | Innovative Intrathecal Solutions, Inc. dba Innovative Compounding Pharmacy |
| Subject | Compounding Pharmacy/Adulterated Drug Products |
| Issue date | Sep 19, 2018 |
| Posted date | Mar 19, 2022 |
| Issuing office | San Francisco District Office |
| Product type | Drugs |
| CFR sections cited | 200.10(b), 211.28(a), 211.42(c)(10)(iv), 211.42(c)(10)(v), 211.56(a), 211.113(b), 211.166(a), 211.167(a), 210.1(b) |
| Inspection city | Murrieta |
| Inspection ZIP | 92562-8007 |
| Inspection start date | Oct 2, 2017 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: